Phase 1 Randomised Clinical Trial of the First-in-Class KMO inhibitor KNS366

Our company, Kynos Therapeutics Ltd., is developing a new kind of medicine to treat diseases caused by inflammation, especially kidney damage after major open heart surgery, and that may also have a use against cancer. This new medicine affects the metabolism of cells and tissues, and especially how cells of the immune system function. Our new medicine has all the characteristics required to be developed into a successful drug for patients, and has been extensively safety-tested in experimental models.\r
\r
In order to continue the new medicines development process, we need to now make sure that this new medicine is safe for human use. In this project, which is a clinical trial recruiting healthy volunteers, we will carefully measure the safety of the new medicine by giving a very low dose of the new medicine and gradually increasing the dose across different groups of volunteers, ultimately reaching a dose level that we expect will be the dose used in patients. Throughout all of this process, the safety of the volunteers will be our foremost priority.\r
\r
If our project is successful and the medicine is safe in humans, and blood tests show that the medicine changes metabolism in the way we expect it to, we will have made a game-changing leap forward and opened the door to follow-on clinical trials involving patients, initially to trial whether the medicine can prevent kidney damage after major open heart surgery.